personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Outcome of a single intravitreal bevacizumab injection in retinopathy of prematurity

Session Details

Session Title: Vascular Diseases III

Session Date/Time: Sunday 29/09/2013 | 08:00-10:00

Paper Time: 09:36

Venue: Hall 3 (Level 0)

First Author: A.Souka EGYPT

Co Author(s):    S. Soliman              

Abstract Details

Purpose:

To evaluate the efficacy of a single intravitreal bevacizumab injection in controlling disease progression in eyes with stage III retinopathy of prematurity (ROP) and in facilitating subsequent pars plana vitrectomy in cases of stage IV ROP.

Setting:

Faculty of Medicine, Alexandria Main University Hospital (fundus photography and follow up) i-Care eye Hospital (intravitreal injection)

Methods:

A retrospective review of the records of premature infants that had ROP and received a single intravitreal bevacizumab injection (0.625 mg/0.25 ml) was performed. Eyes that completed 6 months of post injection follow up were included. The need for additional treatments (laser, cryotherapy, re-injection or surgery) to control disease progression for stage III ROP was evaluated. The surgical steps and outcome in eyes with stage IV ROP after injection were evaluated.

Results:

Records of 41 eyes of 21 premature infants (11 of them are females) with ROP (35 eyes with stage III and 6 eyes with stage IV b) were reviewed. 100% of eyes injected for stage III ROP needed no additional treatment and 80% of eyes (28/35) showed evidence of peripheral retinal vascularization at 6 months of follow up. The surgeon observed easiness of fibrovascular tissue dissection with less bleeding in 100% of preoperatively injected stage IV b eyes in comparison to his previous surgical experience in similar non injected cases. The extent of preoperative retinal detachment and fibrovascular proliferation inversely correlated with the final postoperative anatomical outcome.

Conclusions:

A single intravitreal bevacizumab injection is sufficient in controlling disease progression in eyes with stage III ROP without the need of additional treatments. Preoperative intravitreal bevacizumab facilitated surgical intervention with less bleeding and easier dissection in eyes with stage IV b ROP. The extent of preoperative retinal detachment is the main determining factor in the final anatomical outcome in stage IV b ROP.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy